See the DrugPatentWatch profile for Nplate
What patents cover Nplate (romiplostim) and who holds them?
Nplate is the brand name for romiplostim, a thrombopoietin receptor agonist. The key patent picture typically includes patents on the drug substance/composition, specific manufacturing approaches, and the therapeutic use claims. Which exact patent numbers apply depends on the country (for example, the US vs. Europe) and the specific marketing authorization route, and those details are published in each jurisdiction’s patent and regulatory filings.
If you tell me the country (US, UK, EU, Canada, etc.), I can map the specific Nplate/romiplostim patent families and their expected timing using the relevant registries.
When does the Nplate patent expire (and how long does protection last)?
Patent expiry for Nplate depends on (1) the filing and grant dates of the relevant patents in each jurisdiction and (2) any extra regulatory exclusivity terms that may extend market protection even after the core patent expires. Exact dates also vary by geography.
If you share the country you care about, I can provide the expected expiry window and whether any exclusivity provisions are likely to delay generic/biosimilar entry.
Can biosimilars enter before the Nplate patent expires?
In most cases, competitors cannot market a competing product in the same jurisdiction until the blocking patents or exclusivity protections expire or are successfully challenged. Even when early scientific development is possible, commercial launch typically waits for legal clearance.
The relevant question becomes whether the competitor is trying to launch:
- a biosimilar/biologic intended to rely on Nplate’s reference biologic data, or
- a different but functionally similar product with its own regulatory dossier.
The answer varies by jurisdiction and by whether specific patents are invalidated or designed around.
What patents matter most for blocking generic or biosimilar launch?
For a biologic like romiplostim, the most litigated and blocking elements often fall into:
- composition/formulation or specific molecular design claims,
- method-of-manufacture claims (process and control parameters),
- and sometimes dosing or therapeutic-use claims tied to effectiveness/safety.
The practical “launch blocker” is whichever patents are still in force at the time a biosimilar marketer seeks approval/launch in a given market.
Has Nplate faced patent challenges or litigation?
Patent challenges are common around high-value biologics once the first meaningful expiration approaches. However, the specific status—who sued whom, which patents were asserted, and what rulings occurred—requires checking the docket and national case records for the jurisdiction you mean.
Tell me the country and, if you know it, the competitor name you’re thinking of, and I can summarize the litigation and its impact on market timing.
Where can I look up the exact Nplate patent numbers and status?
The most reliable sources are jurisdiction-specific:
- US: FDA’s biologics/biosimilar reference materials and Orange Book-style listings where applicable, plus patent listings tied to the biologics license/approval pathway.
- EU/UK: national patent registers and EPO family data, plus any linkage to marketing authorization documents.
Because patent numbers and expiry dates are jurisdiction-dependent, the best next step is specifying the market.
---
Quick question so I can give exact patent expiry dates
Which market are you asking about: US, EU/UK, Canada, or another country?